Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3652964 | 0.94 | USP2 (0.42) | USP2SMN1; SMN2ESR2EPHX1ELANE | |
| SCHEMBL173426 | 0.91 | HPGD (0.44) | USP2SMN1; SMN2EPHX1ELANENR1H2 | |
| SCHEMBL171462 | 0.86 | EPHX1 (0.50) | USP2SMN1; SMN2EPHX1ELANEMAPT | |
| SCHEMBL28441771 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2ESR2EPHX1NR1H2 | |
| SCHEMBL21241481 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2ESR2EPHX1NR1H2 | |
| SCHEMBL31561924 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2ESR2EPHX1NR1H2 | |
| SCHEMBL104498 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2ESR2EPHX1NR1H2 | |
| SCHEMBL12908934 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2ESR2EPHX1NR1H2 | |
| SCHEMBL31372297 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2ESR2EPHX1NR1H2 | |
| SCHEMBL16220613 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2ESR2NR1H2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112250616-B | Preparation method of 4-oxo-3, 4-dihydropyridine-1 (2H) -carboxylic acid tert-butyl ester | 南京合巨药业有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-112250616-A | Preparation method of 4-oxo-3, 4-dihydropyridine-1 (2H) -carboxylic acid tert-butyl ester | 南京合巨药业有限公司 | 2021-01-22 | — | — | CN | claimed |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4650351-A1 | INHIBITOR OF COMPLEMENT FACTOR B | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12453734-B2 | Modulators of rho-associated protein kinase | REDX PHARMA LIMITED (GB) | 2025-10-28 | — | — | US | disclosed |
| US-20250326749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4635570-A2 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20030092727-A1 | Hydroxamic and carboxylic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-05-15 | — | — | US | disclosed |
| EP-1292576-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-6506773-B2 | For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration | DARWIN DISCOVERY LTD. (GB) | 2003-01-14 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-02-21 | — | — | US | disclosed |
| WO-2001087844-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
| EP-1076058-A1 | $g(b)-LACTAM COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-02-14 | — | — | EP | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | USP2 2859/4885SMN1; SMN2 3119/4885ESR2 4172/4885 |
| US-20250326749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, SLC26A4, PKD2 | USP2 4188/4885SMN1; SMN2 2169/4885ESR2 4433/4885 |
| US-12453734-B2 | Modulators of rho-associated protein kinase | ROCK2, ROCK1, RHOA | USP2 2567/4885SMN1; SMN2 3144/4885ESR2 2425/4885 |
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | USP2 1432/4885SMN1; SMN2 2728/4885ESR2 1933/4885 |
| US-20030092727-A1 | Hydroxamic and carboxylic acid derivatives | UACA, HCAR2, HCAR1 | USP2 2883/4885SMN1; SMN2 4073/4885ESR2 2659/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | USP2 3689/4885SMN1; SMN2 1015/4885ESR2 1945/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | USP2 1543/4885SMN1; SMN2 4623/4885ESR2 1515/4885 |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, HCAR3 | USP2 4491/4885SMN1; SMN2 4289/4885ESR2 1980/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | USP2 4384/4885SMN1; SMN2 4780/4885ESR2 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.